BioMarin agreed to acquire Amicus Therapeutics in an all‑cash deal that values Amicus at roughly $4.8 billion. The boards approved the transaction; BioMarin will take on Amicus’ approved therapies for Fabry and Pompe disease (Galafold; Pombiliti/Opfolda) and U.S. rights to the late‑stage candidate DMX‑200. The buy adds immediate commercial revenue and a late‑stage asset while accelerating BioMarin’s pivot back into marketed rare‑disease products. The deal is slated to close in mid‑2026 and positions BioMarin to use global reach and scale to drive growth and cost synergies.